Azacitidine
| Evidence Level: L5 | Predicted Indications: 51 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Azacitidine |
| DrugBank ID | DB00928 |
| Brand Names (EU) | Azacitidine Accord, Azacitidine betapharm |
| Evidence Level | L5 |
| Predicted Indications | 51 |
| Top Prediction Score | 98.81% |
Approved Indication (EMA)
Azacitidine betapharm is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS), chronic myelomonocytic leukaemia (CMML) with 10 % to 29 % marrow blasts without myeloproliferative disorder, acute myeloid leukaemia (AML) with 20 % to 30 % blasts and multi-lineage dysplasia, according to World Health Orga
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acute myeloid leukemia with t(8;21)(q22;q22) translocation | 98.81% | DL |
| 2 | acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) | 98.74% | DL |
| 3 | acute myeloid leukemia with CEBPA somatic mutations | 98.71% | DL |
| 4 | bulbar polio | 98.59% | DL |
| 5 | refractory cytopenia of childhood | 98.20% | DL |
| 6 | unclassified myelodysplastic syndrome | 98.10% | DL |
| 7 | partial deletion of the long arm of chromosome 5 | 97.88% | DL |
| 8 | aregenerative anemia | 97.88% | DL |
| 9 | severe congenital hypochromic anemia with ringed sideroblasts | 97.56% | DL |
| 10 | 5q35 microduplication syndrome | 97.48% | DL |
| 11 | myelodysplastic syndrome | 97.26% | DL |
| 12 | neuralgic amyotrophy | 96.20% | DL |
| 13 | amyotrophic neuralgia | 95.87% | DL |
| 14 | therapy related acute myeloid leukemia and myelodysplastic syndrome | 94.60% | DL |
| 15 | acute myeloid leukemia with t(8;16)(p11;p13) translocation | 94.04% | DL |
| 16 | familial thrombocytosis | 93.09% | DL |
| 17 | acute myeloid leukemia with minimal differentiation | 92.98% | DL |
| 18 | acute myeloid leukemia with t(9;11)(p22;q23) | 92.94% | DL |
| 19 | acute myeloid leukemia with t(6;9)(p23;q34) | 92.45% | DL |
| 20 | inherited acute myeloid leukemia | 92.26% | DL |
Showing top 20 of 51 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.